W

Waters

High-performance analytical instruments, software, and services

Intern – Field Service

Spring 2026, Summer 2026Updated Deadline 2/24/27
No salary listed
Internship
Bachelor's
Franklin, MA, USA
In Person
Hardware EngineeringBoard & Electronics Design

About the job

Requirements
  • Currently pursuing a B.A. or B.S. degree in Chemistry or Biology or related field.
  • Proven ability to critically evaluate the situation at hand with solid verbal and written communication skills.
  • Having the skills to understand and work with machinery, and can demonstrate a high level of customer service.
Responsibilities
  • Supporting the field mentor during system installation, conducting routine on-site corrective repairs and (PM) preventative maintenance on Waters’s systems.
  • Assisting Field Service Specialists on the Alliance Systems and supporting a team of service specialists whose purpose is to build & maintain relationships with customers and provide them with best-in-class solutions.
  • Assisting with performance maintenance planning, organization, and documentation.
  • Engaging with the customers of Waters and assisting with evolving our deep relationships which includes visiting the various locations of our customers with your mentor.
  • Attending mentorship sessions within the Sales and Services organization.

About the company

Waters provides analytical system solutions, software, and services for scientists across biopharma, clinical research, forensics, life science, food and beverage, and environmental sectors. Its products include high-performance instruments such as the BioAccord System, along with optimized software and support services that enable precise and reproducible analytical results. The company differentiates itself by offering end-to-end, integrated hardware, software, and services across a broad range of markets, with a strong emphasis on reproducibility, data insights, and comprehensive customer support. Its goal is to unlock the potential of science by solving critical problems that matter to human health and well-being.

Company Size

10,001+

Company Stage

IPO

Headquarters

Milford, CT

Founded

1958

Get referred to Waters

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 4, 2026 revenue hit $1.645 billion, and Waters raised full-year 2026 guidance.
  • June 24, 2026 IMU Biosciences partnership extends Waters into AI immune-mapping research workflows.
  • September 29, 2026 analysts assigned Waters Moderate Buy with $434.60 target.

What critics are saying

  • BD product regulatory transfers remain unfinished, leaving Waters dependent on BD manufacturing through 2026.
  • China localization for flow instruments risks share loss if 2026 tender qualification slips.
  • Waters' $200 million run-rate synergy target leaves integration failure existential if margins stall.

What makes Waters unique

  • February 9, 2026 BD combination gives Waters diagnostics, biosciences, and analytical breadth.
  • September 14, 2026 FACSDiscover A7 standardizes 50-plus parameter spectral flow cytometry across sites.
  • July 27, 2026 Xevo TQ Absolute XR IVD claims five-times clinical MS sensitivity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

9%

1 year growth

17%

2 year growth

14%
Yahoo Finance
Nov 2nd, 2026
Waters Corporation Q3 earnings preview: 119% revenue growth expected after $1.65B last quarter

Waters Corporation (NYSE:WAT), a scientific instruments company, reports third-quarter earnings on Tuesday morning. Analysts expect revenue to grow 119% year on year, up from an 8% rise in the same quarter last year. Last quarter, Waters beat revenue expectations with $1.65 billion, up 113% year on year. It narrowly beat earnings per share estimates, and its next-quarter revenue guidance met expectations. Analysts have largely held their estimates over the past 30 days. The company has a history of topping Wall Street forecasts. Peers have mixed signals. Avantor's revenue rose 4.6% and Thermo Fisher's rose 9.1%, both beating estimates, yet their shares fell 2.6% and 1.6%. Waters shares are up 5.1% over the past month, at $462.69. The average analyst price target is $465.86.

PR Newswire
Oct 28th, 2026
Waters launches AI-Powered Peak Integration expanding its suite of premium AI subscription capabilities for Empower Software.

Waters launches AI-Powered Peak Integration expanding its suite of premium AI subscription capabilities for Empower Software. Oct 28, 2026, 08:00 ET * Advances Waters' strategy to bring trusted AI, ML, and automation capabilities to the 500,000 Empower(TM) Software users who run the world's regulated chromatography labs and support the release of over 80% of medicines globally * AI-Powered Peak Integration transforms chromatography data processing in regulated environments, using AI to reduce manual interventions by up to 95% while delivering 76% greater accuracy and a 72% reduction in user-to-user variability * Joins a growing portfolio of premium AI capabilities Waters is building directly into Empower Software, uniquely enabling AI, ML, and automation inside the validated environment where highly protected customer data resides, with no compromise to integrity, traceability, or compliance MILFORD, Mass., Oct. 28, 2026 /PRNewswire/ - Waters Corporation (NYSE: WAT) today announced AI-Powered Peak Integration, the next step in its strategy to build intelligent AI, machine learning, and automation cloud-based capabilities directly into Empower Software, the chromatography data system of record for regulated laboratories worldwide. "Waters is using AI to help customers bring drugs to market faster and to increase the quality testing of manufactured molecules," said Tina Wu, Senior Vice President, Waters Analytical Sciences, Waters Corporation. "Our Empower Software has been the system of record for regulated chromatography for decades, holding terabytes of validated data for each customer, inside their own workflows, and under their own control. The potential behind compliant data at scale is one that no other platform can offer as we enable customers to realize the benefits of AI within their regulated workflows." Wu continued, "Our customers want the greater speed, accuracy, and productivity that AI brings, without giving up control of their data or the compliant audit trail behind it. That is why it is a central pillar of how we are advancing Empower Software as AI transforms the laboratory. Every one of these premium subscription-based capabilities reaches our large and growing installed base, so each release makes Empower Software more valuable to the laboratories already running it. We have a full pipeline of capabilities ahead as we deliver on our strategy to advance Empower Software into the connected, intelligent platform on which regulated science runs." Enabling Unique AI Capabilities Customers Can Use Beyond Research in a Deliberate Strategy Developed in Deep Partnership with Pharma Waters is collaborating with several large pharmaceutical customers and academic institutions to create autonomous, AI-enabled research, development and QA/QC capabilities that follow the molecule, from discovery to release. This builds on two abilities unique to Waters: 1) supporting research workflows and then subsequently moving them directly into compliant settings on a single platform, and 2) enabling AI inside that compliant environment, so customers realize the benefits of AI without giving up control of their data or the compliant audit trail behind it. The same approach is advancing in biologics, where Waters is applying AI, automation, and analytical instrumentation to bioanalytical characterization, bringing large molecule workflows more closely toward the compliant foundation customers already expect for small molecules. Turning Decades of Compliant Data into an AI Advantage for Customers Designed for high-throughput, compliant applications, where consistency and audit traceability are key, Waters Empower AI capabilities drive significant efficiency and productivity gains by reducing manual effort and variability in pharmaceutical late-stage development and manufacturing QC applications, while improving accuracy of results. Because the capabilities are being built directly into Empower Software, they operate inside the validated environment where highly protected customer data already resides, bringing AI and ML directly to the data, with no compromise to integrity, traceability, or compliance. Using AI to Automate One of the Most Manual Steps in Chromatography Manual peak integration is the largest source of variability in chromatographic results and one of the most time-consuming steps in data review. Waters' AI/ML-powered peak integration automates this step in Empower Software using artificial intelligence and machine learning trained on each laboratory's own data, removing noise peaks, combining high molecular weight peaks and editing baselines, with explainable outputs that allow analysts to review results quickly and with confidence. Version-controlled, no-drift models maintain consistent performance until the laboratory chooses to retrain and approve a new model. In a pilot with a large pharmaceutical customer, side-by-side review of 400 chromatograms reduced manual interventions from 90 under current practice to 4 with AI/ML-powered peak integration, a 95% reduction.[1] User testing also showed 50% faster review and 72% lower user-to-user variability, reducing analyst bias and supporting data integrity.[2] AI-Powered Peak Integration is a new premium tier capability available to customers on subscription. Waters is enrolling customers now for early access beginning in December 2026, with validated, compliant deployment to follow in mid-2027. Building on AI-Powered Anomaly Detection, Launched in 2025 Peak integration is the latest step in Waters' strategy to make Empower Software the connected, intelligent platform on which regulated science runs. The first was AI/ML Anomaly Detection, launched in Empower Software in February 2025, which uses machine learning to compare target results across chromatography data, surface deviations for review, and explain the attributes contributing to each anomaly. About Waters Corporation: Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~15,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about. Waters and Empower are trademarks of Waters Corporation or its affiliates. References: * Waters internal pilot study with a global pharmaceutical partner, 2025. Data on file, Waters Corporation. * Waters Immerse Research Lab customer evaluation, 2026. Data on file, Waters Corporation. Molly Gluck Director, Product and Thought Leadership Communications Waters Corporation +1.508.498.9732 [email protected] SOURCE Waters Corporation

PR Newswire
Oct 28th, 2026
Waters launches AI peak integration for Empower, cutting manual interventions by up to 95%

Waters Corporation (NYSE: WAT) has launched AI-Powered Peak Integration, a premium subscription feature for its Empower Software, the chromatography data system used by regulated laboratories worldwide. The tool automates manual peak integration, a major source of variability in results. It uses AI and machine learning trained on each laboratory's own data, and runs inside the validated environment where customer data is held. In a pilot with a large pharmaceutical customer, manual interventions across 400 chromatograms fell from 90 to four, a 95% reduction. Testing also showed 50% faster review and 72% lower user-to-user variability. Waters is enrolling customers for early access from December 2026. Validated, compliant deployment will follow in mid-2027.

MarketScreener
Oct 23rd, 2026
Labcorp and Waters Corporation announce partnership to expand access to fda-approved BD Onclarity HPV Assay.

Labcorp and Waters Corporation announce partnership to expand access to fda-approved BD Onclarity HPV Assay. Published on 10/23/2026 at 10:20 am EDT S&P Capital IQ Labcorp and Waters Corporation announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's nationwide laboratory network beginning in late 2026. Labcorp will provide these HPV testing options to support its clinician programs, Gaps in Care health plan programs, and Labcorp OnDemand consumer channel. The BD Onclarity HPV Assay is the only FDA-approved HPV test that supports all American Society for Colposcopy and Cervical Pathology (ASCCP) Enduring Risk-Based Management Guidelines. Certain HPV genotypes, including types 16, 18 and 45, are associated with an increased risk of cervical cancer, making genotype-specific information important for patient management. As HPV vaccination has reduced infections from HPV types 16 and 18, other high-risk HPV strains now account for a growing share of cervical disease, particularly among younger, vaccinated populations. The BD Onclarity HPV Assay offers extended genotyping that individually identifies HPV types 16, 18, 31, 45, 51 and 52 along with three sets of strategically pooled results, regardless of collection method, making it the most comprehensive HPV screening tool available in the U.S. Waters and Labcorp intend to offer the BD Onclarity HPV Assay by the end of 2026. (C) S&P Capital IQ - 2026

PR Newswire
Oct 5th, 2026
CellCarta establishes strategic partnership with Waters to advance companion diagnostics development.

CellCarta establishes strategic partnership with Waters to advance companion diagnostics development. Oct 05, 2026, 09:15 ET Collaboration combines CellCarta's global clinical trial testing capabilities with Waters' standardized flow cytometry platforms and expertise MONTREAL, Oct. 5, 2026 /PRNewswire/ - CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced a strategic partnership with Waters Corporation, a global leader in life sciences and diagnostics, creating a framework to jointly pursue companion diagnostic (CDx) and next-generation flow cytometry opportunities with pharmaceutical and biotechnology companies. The collaboration will initially emphasize flow cytometry-based programs. For CDx opportunities, the partnership aims to provide sponsors with a coordinated path from biomarker strategy through clinical development, regulatory submission and global commercialization. The complementary expertise of CellCarta and Waters spans assay innovation, development, validation, and global implementation. Waters provides underlying technology capabilities, including instrumentation, reagents, standardized panels, assay development, software analysis, and, where appropriate, custom reagent and IVD commercialization. CellCarta leverages its extensive biomarker, translational research, and clinical development expertise to integrate and deploy the assay across its global CDx Lab Network, supporting Phase I-III clinical trial testing, generation of analytical and clinical evidence, regulatory and logistics support, and commercial laboratory services. Together, the companies aim to deliver standardized and globally scalable solutions for precision medicine. The existing platform alignment between CellCarta's CAP-accredited laboratory's capabilities in Jining, China and BD flow cytometry platforms create a practical foundation for global sponsors seeking to include China in future multinational CDx and biomarker programs, as well as China-based biopharmaceutical companies preparing to expand their therapies and diagnostic strategies globally. "For our biopharmaceutical sponsors, the business value of this partnership is clear: a more connected path from biomarker strategy through global clinical development and, where appropriate, commercialization," said Todd Chermak, President of CellCarta. "By combining CellCarta's end-to-end laboratory capabilities with Waters' diagnostic and CDx development expertise, and flow cytometry platforms, we can help sponsors reduce complexity, preserve program continuity and make earlier, more informed decisions about how to scale their programs. We are already engaging pharmaceutical and biotechnology companies on near-term opportunities where this combined model can make a meaningful difference." "In particular for China, this partnership has the potential to help sponsors pursue more consistent China-to-global and global-to-China pathways while accounting for cross-border, regulatory, and operational requirements," said Christopher Ung, Chief Scientific Business Officer and Head of China Strategy for CellCarta. "Together, we can connect patient selection with treatment-response assessment - and make China part of that strategy from the beginning." "Next-generation flow cytometry is expanding what laboratories can see by combining highly sensitive rare-cell analysis with greater standardization across the entire workflow," said Brent Gaylord, VP/GM Reagents, Waters Biosciences, Waters Corporation. "By combining CellCarta's contract research organization expertise with Waters' clinical assay development expertise and integrated instruments, reagents, and informatics, this collaboration is designed to help biopharmaceutical sponsors translate high-value cellular insights into clinical assays that can be consistently deployed across programs and geographies." About CellCarta CellCarta is a leading global CRO laboratory to the biopharmaceutical industry. With CAP accreditations and CLIA certifications for specific testing methods and facilities in Canada, the United States, Belgium, Australia and China, CellCarta provides a wide range of biomarker testing services and customized solutions to world-renowned pharmaceutical companies. By integrating analytical platforms in immunology, histopathology, proteomics and genomics, along with sample management and logistics services, CellCarta supports the entire drug-development cycle from discovery to late-stage clinical trials. Visit cellcarta.com and connect with CellCarta on LinkedIn and X. Media Contacts CellCarta Stéphanie Bussières-Marmen, PhD Director, Global Marketing [email protected] Melanie Williams Senior Marketing Communications Specialist, Supreme Optimization [email protected] SOURCE CellCarta

INACTIVE